Having cemented its name in long-read sequencing, PacBio takes a stab at Illumina with new short-read tech
Pacific Biosciences, or PacBio for short, made its name in long-read DNA sequencing — the technology recently used to sequence the entire human genome — filling in a niche market where typical short-read DNA sequencers, like the ones on which Illumina built its dominance, could not go. But now, PacBio wants to take on Illumina directly.
Tuesday evening, PacBio announced plans for a short-read sequencer known as Onso. First, the sequencer will be beta-tested by scientists at The Broad Institute, Corteva Agriscience and Weill Cornell Medicine, after which PacBio expects to launch its new short-read machines in the first half of next year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.